Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

Author： Dorsey Philip   Keel Christopher   Klavens Meghan   Hellstrom Wayne JG  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.7, 2010-05, pp. : 1109-1122

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

By Bruzziches Roberto  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1333-1344

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment

By  

Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. : 3486-3495

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction

By  

Current Pharmaceutical Design, Vol. 12, Iss. 27, 2006-09 ,pp. : 3467-3484

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 5 inhibitors and erectile dysfunction

By Sandner Peter   Svenstrup Niels   Tinel Hanna   Haning Helmut   Bischoff Erwin  

Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 1, 2008-01 ,pp. : 21-33

Informa Healthcare

Access to resources Recommend Favorite

Novel PDE5 inhibitors for the treatment of male erectile dysfunction

By Kalsi JS   Bahadur G   Muneer A   Ozturk O   Christopher N   Ralph DJ   Minhas S  

Reproductive BioMedicine Online, Vol. 7, Iss. 4, 2003-10 ,pp. : 456-461

Reproductive Healthcare Ltd

Access to resources Recommend Favorite